Global Hyperlipidemia Market – Industry Trends and Forecast to 2029

Análisis y tamaño del mercado

En los últimos años, se prevé que el mercado de la hiperlipidemia crezca rápidamente durante el período de pronóstico. La hiperlipidemia es una afección muy prevalente, especialmente en los países ricos. También está aumentando a nivel mundial. 94 millones de personas mayores de 20 años en los Estados Unidos tienen niveles altos de colesterol total. Esto equivale a aproximadamente la mitad de todos los adultos en los Estados Unidos. Las personas con hiperlipidemia no tratada tienen el doble de probabilidades que las que tienen niveles normales de colesterol de desarrollar enfermedad de las arterias coronarias (EAC). Esto puede causar arterias obstruidas, lo que puede provocar ataques cardíacos, accidentes cerebrovasculares y otras complicaciones peligrosas. Por otro lado, la hiperlipidemia suele ser muy tratable y estas situaciones de emergencia se pueden evitar.

Data Bridge Market Research analiza que el mercado de hiperlipidemia se valoró en USD 18,97 mil millones en 2021 y se espera que alcance los USD 23,84 mil millones para 2029, registrando una CAGR de 2,90% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Definición de mercado

La hiperlipidemia es una enfermedad caracterizada por la presencia de niveles elevados de grasa en el torrente sanguíneo. Los accidentes cerebrovasculares, la enfermedad vascular periférica , la obesidad, la aterosclerosis , la hipertensión, la diabetes y los trastornos cardiovasculares pueden ser causados ​​por niveles anormalmente elevados de lípidos y/o lipoproteínas. Los factores genéticos, los malos estilos de vida y una mala alimentación son las causas más comunes. Las estatinas, los inhibidores de la proproteína convertasa subtilisina/kexina tipo 9 (PCSK9), los secuestradores de ácidos biliares, los derivados del ácido fíbrico o fibratos y los medicamentos combinados y otros medicamentos antihiperlipidémicos son algunos de los tratamientos más utilizados para la hiperlipidemia. Esta afección también se denomina colesterol alto. 

Alcance del informe y segmentación del mercado

Dinámica del mercado de la hiperlipidemia

Conductores

• Aumento de la prevalencia de hiperlipidemia

Se estima que la creciente prevalencia de la hiperlipidemia en todo el mundo impulsará el crecimiento del mercado. Junto con esto, la creciente conciencia entre la población sobre el riesgo de enfermedades cardiovasculares debido a la hipercolesterolemia persistente impulsará la tasa de crecimiento del mercado de la hiperlipidemia. Según la Organización Mundial de la Salud (OMS), las enfermedades cardiovasculares (ECV) se cobraron la vida de 17,9 millones de personas en todo el mundo en 2019, lo que representa el 32% de todas las muertes.

• Aumentar la inversión en infraestructura sanitaria

Otro factor importante que influye en la tasa de crecimiento del mercado de la hiperlipidemia es el aumento del gasto sanitario, que ayuda a mejorar su infraestructura. Además, varias organizaciones gubernamentales tienen como objetivo mejorar la infraestructura sanitaria aumentando la financiación, lo que influirá aún más en la dinámica del mercado.

• Creciente número de población geriátrica

Se estima que el aumento de la población geriátrica impulsará la expansión del mercado durante el período de pronóstico de 2022 a 2029. Según la Organización Mundial de la Salud (OMS), se espera que la población geriátrica mundial, que se estimó en más de 524 millones en 2010, aumente a casi 2 mil millones para 2050. Debido a sus sistemas inmunológicos comprometidos, los geriátricos son más susceptibles al colesterol y las enfermedades cardiovasculares, lo que se estima que impulsará aún más la tasa de crecimiento del mercado.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hyperlipidemia market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of hyperlipidemia market. Surging use of statin therapy and rising incidences of obesity are the major factors anticipated to flourish the market's growth rate during the forecast period of 2022-2029.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hyperlipidemia market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of hyperlipidemia during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hyperlipidemia market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This hyperlipidemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hyperlipidemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Hyperlipidemia is a chronic, progressive condition that necessitates dietary and lifestyle adjustments and the use of additional lipid-lowering drugs. Patients with premature coronary artery disease (CAD), defined as CAD that develops in males before the age of 55 to 60 and females before the age of 65, had the greatest level of hyperlipidemia. Hyperlipidemia is around 75-85 percent in the above-mentioned circumstances, compared to 40 to 48 percent in a control population of the same age, but without early coronary artery disease.

Hyperlipidemia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hyperlipidemia Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the hyperlipidemia market.

Recent Development

• In December 2021, Novartis announced the U.S. Food and Drug Administration (FDA) approval of Leqvio (inclisiran). It is the first and only small interfering RNA (siRNA) therapy that lowers low-density lipoprotein cholesterol with two doses annually, after an initial dose and one at three months. Leqvio lowers LDL-C levels in the bloodstream by enhancing the liver's natural ability to suppress the creation of a protein that contributes to excessive cholesterol levels in the bloodstream.

Global Hyperlipidemia Market Scope

The hyperlipidemia market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Familial
• Acquired

Treatment

• Statins
• PCSK9 Inhibitors
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• Fibric Acid Derivatives
• Combination
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hyperlipidemia Market Regional Analysis/Insights

The hyperlipidemia market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the hyperlipidemia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the hyperlipidemia market because of the rising prevalence of hyperlipidemia and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to increasing number of geriatric population in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel themarket's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hyperlipidemia Market Share Analysis

The hyperlipidemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hyperlipidemia market.

Some of the major players operating in the hyperlipidemia market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Bristol-Myers Squibb Company (U.S.)
• Eli Lilly and Company (U.S.)
• Regeneron Pharmaceuticals Inc. (U.S.)
• Amgen Inc. (U.S.)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Alnylam Pharmaceuticals, Inc. (U.S.)
• Dr. Reddy's Laboratories Ltd. (India)
• Esperion Therapeutics, Inc. (U.S.)
• Formac Pharmaceuticals N.V. (Belgium)

SKU-54515